Table 2.
Randomized controlled trials in male androgenic alopecia
| Author, year | Age, years | Intervention group | Comparison | Duration, weeks | Results, mean difference hair density/cm2 (SD) between baseline and end of the study | Side effects |
|---|---|---|---|---|---|---|
| Olsen et al, 200215 | 36.5 (mean) | ●2% MS twice daily, N=141 | ●Placebo, N=78 | 48 | ●2% MS: 12.7 (20.7) | ●2% MS: pruritus 1%, headache 0.6% |
| ●5% MS twice daily, N=139 | ●5% MS: 18.6 (25.4) ●Placebo: 3.9 (21.7) |
●5% MS: pruritus 4%, headache 3% | ||||
| Olsen et al, 200732 | 39.2 (mean) | ●5% MF twice daily, N=180 | ●Placebo, N=172 | 16 | ●5% MS: 20.9 (22.5) ●Placebo: 4.7 (19.7) |
Erythema 3.9%, dryness/scaling 2.8%, folliculitis 1.1% |
| Berger et al, 200333 | 40 (mean) | ●5% MS twice daily plus placebo shampoo, N=50 | ●Placebo shampoo, N=50 | 26 | ●5% MS: 12.3 ●Placebo: −0.58 |
Local intolerance 7% |
Abbreviations: MS, minoxidil solution; MF, minoxidil foam.